In this Exclusive Interview, Nancy D'Hondt talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the need for diabetes education and ways to reach people at risk as well as those in need of support.
Read More »Production Assistant, Diabetes In Control
Sedentary Behavior During Pregnancy and Neonatal Adiposity
Lifestyle intervention in pregnancy might reduce adverse effects of maternal obesity on neonatal adiposity.
Read More »Statins And The Risk of Developing Diabetes
Recent studies have shown that statins can raise blood sugar and more patients on statin therapy were diagnosed with diabetes mellitus.
Read More »Fasting Glucose Estimates Absolute Risk for CVD
Monitoring glucose in midlife may help prevent future cardiovascular disease, according to a study published in Diabetes Care.
Read More »First Dual SGLT-1/2 Inhibitor For Adults With Type 1 Declined Approval
Sanofi and Lexicon to continue any required studies in effort to move sotagliflozin forward.
Read More »New FDA Extension for Farxiga and Xigduo XR
Dapagliflozin’s updated package insert confirms efficacy and safety profile for patients with moderate chronic kidney disease.
Read More »International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #170: Molecular Genetics of Type 1 Diabetes Part 7
Clinical utility of T1DM susceptibility genes: One of the goals of genetic studies of complex disease is to identify a profile of susceptibility variants that can be used to predict an individual’s risk of developing a given disease. The long prodrome for T1DM, characterized by progressive loss of beta-cell mass, provides an attractive opportunity for intervention to prevent disease development if “at-risk” individuals can be identified. Currently the best markers of disease risk are a positive family history of T1DM and the presence of autoantibodies to islet cell proteins. Over 90% of T1DM patients have no affected relatives, however, so effective preventive efforts will need to target the general population. Unfortunately screening such huge numbers of individuals for islet autoantibodies is logistically unfeasible, particularly given the need for repeated annual testing for those with a negative result. Genetic markers are therefore needed to stratify risk in the general population,
Read More »New Oral GLP-1 Application Submitted to FDA
Novo Nordisk requests approval for new type 2 treatment with heart benefits.
Read More »The Effect of Metformin On Patients Who Are Pregnant and Have PCOS
Treatment throughout pregnancy may reduce rate of miscarriage or preterm delivery.
Read More »Does Canagliflozin Increase Risk of Fracture In Patients With Diabetes?
CANVAS Program shows reduced heart events but increased risk of side effects.
Read More »